Tame Impala continued to drop breadcrumbs on Tuesday with the announcement of Rushium “clinical trials” across the country, including at festivals such as Bonnaroo and Firefly.
The announcement comes just one day after the release of a cryptic video announcing Kevin Parker‘s acquisition of minor equity in a fake Australian biomedical company, AionWell® L.T.d.
According to a press release shared on Tuesday, AionWell is responsible for a groundbreaking new drug, Rushium. The drug, which is about as real as euphoria from 90210, is supposedly effective in treating Acute Time Metagrobolization in Cells (ATMiC) in patients between 16 to 95 years of age.
“ATMiC is a common cellular condition within the brain’s Suprachiasmatic nucleus, much of the research into this condition is cutting edge and still being performed,” the press release reads. “Based on the current findings, ATMiC could affect up to half of the pop ulation [sic]. Currently there are no medications approved for this condition and the only treatment is supportive care and third dose mesothermal procedure.”
AionWell’s Phase 1 clinical trials of Rushium in the United States are set to commence on September 4th at Bonnaroo in Manchester, TN, and conclude on November 9th in Houston, TX. These trials also just so happen to coincide with Tame Impala’s previously scheduled shows.
See a full list of dates below, a confusing graph included with the press release, and a video announcing Rushium. Visit Tame Impala’s website to try and unravel the mystery.
Tame Impala – Rushium Announcement
[Video: Tame Impala]
Whatever Rushium is, it marks the latest evolution for Kevin Parker’s Tame Impala. Back in March, as the pandemic kept most U.S. venues closed, Parker debuted Tame Impala Sound System at a pair of sold-out, maskless club shows in Perth, Australia. Rather than his full band setup, the shows featured new electronic-minded interpretations of the project’s catalog, with Parker at the helm with a myriad of samplers, synths, and sequencers.